These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 20530323)

  • 21. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.
    Rovaris M; Gallo A; Valsasina P; Benedetti B; Caputo D; Ghezzi A; Montanari E; Sormani MP; Bertolotto A; Mancardi G; Bergamaschi R; Martinelli V; Comi G; Filippi M
    Neuroimage; 2005 Feb; 24(4):1139-46. PubMed ID: 15670691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of early brain atrophy in clinically isolated syndromes.
    Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
    Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
    De Stefano N; Stromillo ML; Giorgio A; Bartolozzi ML; Battaglini M; Baldini M; Portaccio E; Amato MP; Sormani MP
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):93-9. PubMed ID: 25904813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis.
    Pontillo G; Cocozza S; Di Stasi M; Carotenuto A; Paolella C; Cipullo MB; Perillo T; Vola EA; Russo C; Masullo M; Moccia M; Lanzillo R; Tedeschi E; Elefante A; Brescia Morra V; Brunetti A; Quarantelli M; Petracca M
    Eur Radiol; 2020 Jul; 30(7):3813-3822. PubMed ID: 32100089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis.
    Calabrese M; Battaglini M; Giorgio A; Atzori M; Bernardi V; Mattisi I; Gallo P; De Stefano N
    Neurology; 2010 Oct; 75(14):1234-40. PubMed ID: 20739644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
    Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans-Coutinho M; Clanet M; Radue EW; Kappos L;
    Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study.
    Hagman S; Raunio M; Rossi M; Dastidar P; Elovaara I
    J Neuroimmunol; 2011 May; 234(1-2):141-7. PubMed ID: 21397339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.
    Kalkers NF; Ameziane N; Bot JC; Minneboo A; Polman CH; Barkhof F
    Arch Neurol; 2002 Oct; 59(10):1572-6. PubMed ID: 12374494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Brain atrophy in clinically isolated syndrome].
    Rojas JI; Patrucco L; Besada C; Bengolea L; Cristiano E
    Neurologia; 2010 Sep; 25(7):430-4. PubMed ID: 20964989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
    Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
    Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aging and Brain Atrophy in Multiple Sclerosis.
    Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    J Neuroimaging; 2019 Jul; 29(4):527-535. PubMed ID: 31074192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study.
    Hagemeier J; Heininen-Brown M; Poloni GU; Bergsland N; Magnano CR; Durfee J; Kennedy C; Carl E; Weinstock-Guttman B; Dwyer MG; Zivadinov R
    J Magn Reson Imaging; 2012 Jul; 36(1):73-83. PubMed ID: 22407571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
    Kalron A; Achiron A; Dvir Z
    NeuroRehabilitation; 2012; 31(2):147-55. PubMed ID: 22951709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The predictive value of gray matter atrophy in clinically isolated syndromes.
    Calabrese M; Rinaldi F; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
    Neurology; 2011 Jul; 77(3):257-63. PubMed ID: 21613600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.